Thus, it seems unlikely this SNP might impact the ACE/AngII/ATR1 axis, which has been associated with tumour cell growth and angiogenesis, partially justifying the absence of clinical impact in NSCLC patients with advanced stage disease. This evidence concerns the gene ACE and non-small cell lung carcinoma.